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We evaluated the efficacy of flecainide acetate (given intravenously to a maximal dose of 2 mg kg ~' and then
orally in a dose of 100 mg b.d. or 100 mg t.d.s.) in the conversion to sinus rhythm of 50 patients exhibiting
supraventricular arrhythmias (39 with atrial fibrillation, 6 with atrial flutter, 4 with supraventricular
tachycardia and one with supraventricular tachycardia in association with the Wolff-Parkinson-White
syndrome). Conversion was achieved in 36 patients (72%) (29 cases with atrial fibrillation, 4 cases
with supraventricular tachycardia, 2 cases with atrial flutter and one case with Wolff-Parkinson-White
syndrome), over a mean period of 7-4 + 9 h.
The patients in which conversion was achieved had arrhythmias which had been in existence for a shorter
time (5-3 + 9-8 days) than those in which conversion was not achieved (16-7 + 26-2 days) (P<001).
The mean dosage of flecainide used to achieve conversion was 2-5 +2-36 mg kg'1. Flecainide appears
to be an effective agent for the conversion to sinus rhythm of atrial fibrillation and supraventricular
tachycardias. Its efficacy in cases of atrial flutter has not yet been demonstrated.
Flecainide acetate, a group I anti-arrhythmic
agent'1 ~4\ has been in clinical use for a short
while. Its efficacy in the treatment of ventricular
arrhythmias'5"8' and of re-entrant junctional
tachycardias'91 has been clearly demonstrated.
There are few studies which have evaluated the
efficacy of flecainide acetate in the treatment of
supraventricular arrhythmias'10'. We therefore
undertook a prospective study of the efficacy of
flecainide in converting supraventricular arrhyth-
mias of recent origin (less than 3 months) to sinus
rhythm.
Patients and methods
PATIENTS
Fifty consecutive patients hospitalized in the
University Hospital of Lausanne (CHUV), were
included in this study. Thirty-nine exhibited atrial
fibrillation, 6 atrial flutter, 4 supraventricular
tachycardia (SV) and one with SV in association
with the Wolff-Parkinson-White syndrome. The
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arrhythmia was dated on the basis of the
appearance of symptoms which could be related to
an arrhythmia subsequently confirmed by an
ECG. Ten patients exhibiting electrolyte imbal-
ance or endocrinological disorders or cardiac
decompensation, pregnancy, unstable angina,
conduction disorders or a poor general state of
health were excluded from the study. All antiar-
rhythmic drugs were discontinued at least 3 times
the half-life of the drug prior to the study. Cardio-
tonics and diuretics were permitted providing they
had been started at least 7 days before the begin-
ning of the study. The clinical characteristics of
each patient are summarized in Table 1. There
were 31 men and 19 women with a mean age of 64
years (ranging from 38 to 93 years). In 21 of these
patients we identified the absence of underlying
organic heart disease. There were 8 cases of
valvular heart disease, 3 cases of congestive cardio-
myopathy, 4 cases of mitral valve prolapse, 7 cases
of ischaemic heart disease, 3 cases of hypertensive
heart disease and one case each of hypertensive
heart disease associated with ischaemic heart dis-
ease, obstructive cardiomyopathy, pericarditis
associated with ischaemic heart disease and peri-
carditis. Thirty-four patients were digitalized and
9 had received a different anti-arrhythmic agent
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without success before the start of the study
(Table 2). One female patient (with obstructive
cardiomyopathy) had been receiving beta blockers
for some months.
PROTOCOL
The protocol was accepted by the Ethical Com-
mittee of the CHUV and all patients gave their
assent orally to being included in the study. Before
the start of the treatment, a 12-lead ECG was
recorded. A monitoring electrocardiogram was
recorded. Flecainide was administered at the rate
of 50 mg diluted in 50 cc of glucose 5% and infused
over lOmin. If the sinus rhythm had not been
restored by 15 min after the end of the infusion, a
second infusion of 50 mg of flecainide was given up
to an initial dose (by the intravenous route) not
exceeding 2 mg kg ~'. The arterial pressure was
measured every 2 min during the intravenous treat-
ment. Oral treatment with 100 mg b.d. or lOOmg
t.d.s. was instituted thereafter (patients weighing
less than 70 kg received 200 mg day"1 and those
whose weight exceeded 70 kg received 300 mg
day"1). Each day, after treatment began, the
patient was questioned in order to establish the
onset of any side-effects and an ECG was recorded.
Arterial pressure was measured 3 times a day. If
an increase in the QRS complex (>0-10s), A-V
block, or abnormal lengthening of the QT interval
became apparent (QTc > 430 ms) or if severe
side-effects were noticed the treatment was dis-
continued immediately. The serum concentration
of flecainide was measured in 17 cases at the time
the conversion to sinus rhythm occurred. The
concentration was measured again 7h after con-
version. In those cases which did not respond
to treatment, the serum concentration was
determined 7 h after the final oral dose. If sinus
rhythm was not restored 48 h after treatment was
begun, the study was discontinued and the patient
was treated conventionally by means of electrical
cardioversion or with traditional anti-arrhythmic
drugs.
STATISTICS
The statistical evaluation comparing the various
parameters was conducted using the Student t test.
BLOOD SAMPLING
Blood samples were taken by means of venous
puncture then centrifuged and the serum was
frozen immediately. The serum concentration of
flecainide was measured by means of gas-liquid
chromatography. Reference samples were exam-
ined systematically at the same time as the plasma
samples.
A reference curve was drawn up and used to
determine the flecainide concentrations. The sen-
sitivity limit of the method is 10 ng ml" l .
Results
Conversion to sinus rhythm was achieved in 36
patients (72%) (29 cases of atrial fibrillation, 4
cases of SV tachycardia, 2 cases of atrial flutter and
one case of Wolff-Parkinson-White syndrome). In
19 cases, the restoration of sinus rhythm occurred
after the first or after the second injection (Table
1). Nine patients had received an alternative anti-
arrhythmic treatment before their inclusion in the
study (Table 2). Of the 14 patients not converted, 4
were converted by electrical cardioversion. In the 6
remaining patients the rhythm disorder persisted
either after the failure of drug treatment (4 cases)
or after failure of electrical cardioversion (2 cases),
(Table 2).
DURATION OF THE ARRHYTHMIA
The duration of the rhythm disorder was
5-3 + 9-8 days in the group of patients converted,
and 16-7 ±26-2 days in the group not converted
(P<00l). One should note that 11 patients (79%)
in the group not converted had arrhythmias which
had persisted for more than 1 day. There were 15
(42%) such patients in the group converted. In 7
cases (50%) of those not converted, the arrhythmia
had lasted for 1 week or more: in the group con-
verted, there were only 6 cases (17%). In all the
cases of flutter, the arrhythmia had lasted for less
than 7 days.
HEART MEASUREMENTS
The mean cardiothoracic index on a standard
chest radiograph was 0-53 + 008 in the group not
converted, and 0-48 + 007 in the group converted
(P<005). The size of the left atrium was not
measured in all cases, but in fact only patients in
whom an echocardiogram was essential underwent
this examination. Nevertheless, the size of the left
atrium was 40+ 11 mm in the group converted,
and 46 + 11 mm in the group not converted (differ-
ence not statistically significant).
AETIOLOGY OF THE ARRHYTHMIA
There was no predominant cardiac pathology in
either of the two groups. However, we established
Table 1 Data for patients converted and not converted
Patient Age(years)
Patients converted
1
2
3
4
5
6
7
g
11
13
15
16
17
18
19
20
22
24
27
28
30
31
32
33
35
36
38
39
40
42
43
44
46
47
48
50
54
72
60
38
66
78
61
36
75
80
85
72
84
93
58
68
55
65
67
92
37
62
64
57
75
38
55
55
56
62
58
52
51
74
72
68
Sex
F
F
M
M
F
F
M
M
M
M
M
M
F
F
M
M
F
F
M
F
M
F
M
M
F
M
M
M
F
M
M
M
M
F
F
M
Diagnosis
(cardiac)
(disease)
none
peric.
none
MVP
IHD
IHD, HHD
none
none
none
VHD
none
none
none
HHD
IHD
MVP
VHD
VHD
none
HHD
none
none
IHD
IHD
none
none
none
none
HHD
peric. IHD
none
MVP
none
none
CCM
IHD
Arrhythmia
flutter
AF
AF
SVT
AF
AF
flutter
W-P-W
AF
AF
AF
AF
SVT
AF
AF
AF
AF
SVT
AF
AF
AF
AF
AF
AF
AF
AF
AF
SVT
AF
AF
AF
AF
AF
AF
AF
AF
Diameter
nftpft
Ul 1CII
atrium
(mm)
—
34
32
30
—
—
—
32
—
—
—
43
—
—
44
33
68
56
—
—
—
—
—
—
47
—
42
36
43
—
28
36
Duration of
arrhythmia
(days)
1
1
1
I
1
?
4
2
1
1
1
1
1
1
21
1
2
3
1
12
1
45
1
1
4
1
28
1
1
10
?
20
1
?
3
1
Cumulative
dose
(mgkg-1)*
1-9
7-5
4-2
0-7
0-85
9-5
2-7
0-68
116
111
5-3
2-5
0-77
3-6
0-59
2-6
1-72
4-6
1-52
31
0-7
3 51
0-63
0-85
3-33
0-79
3-85
0-80
0-63
90
4-44
0-46
0-63
4-7
1-33
111
Side-effects
—
sino-atrial
block
—
—
—
—
—
—
—
—
—
hyperthermia
LBBB
RBBB
—
—
nausea
optical dis.
—
—
—
—
—
—
—
—
—
—
bradycardia
—
—
—
—
—
—
Time
before
conversion
15min
16h
14h
5min
5min
24 h
16h
2min
5min
25 h
14h
3h
5min
12h
5min
6h
lOmin
24 h
lOmin
16h
5min
7h
5min
5min
26 h
5min
24 h
30min
5min
19 h
6h
7min
5min
12h
15 min
15min
index
0-55
0-51
0-43
0-45
0-47
0-56
0-39
0-46
0-44
0-47
0-51
0-48
0-53
0-52
0 51
0-51
0-78
0-50
048
0-50
0-44
0-46
0-48
0-41
0-50
0-45
0-35
0-48
0-56
0-50
0-46
0-45
0-41
0-47
0-56
0-44
Mean
values 63-7±14
Patients not converted
9
10
12
14
21
23
25
26
29
34
37
41
45
49
Mean
values
77
56
62
78
82
62
54
57
53
68
49
55
78
65
64±11
M
M
F
M
F
F
F
F
M
M
M
M
M
M
none
VHD
VHD
none
IHD
OHCM
VHD
VHD
CCM
IHD
CCM
MVP
none
VHD
AF
AF
AF
flutter
AF
AF
AF
flutter
AF
AF
AF
AF
flutter
flutter
40+11
38
60
54
30
36
62
32
42
51
50
57
46±11
5-34 ±9-8
10
10
21
1
5
2
21
3
90
3
7
60
I
16-7 + 26-2
2-59±2-36
7-5
7-3
8-3
9-4
8-6
5-7
10 5
9-3
7-9
10-9
8-6
7-8
10-3
3-5
8-26 ±1-96
7-4 ± 9-2 h
none
none
none
none
none
none
none
none
none
nausea
nausea
none
none
none
0-48 + 007
0-43
0-52
0-55
0-42
0-64
0-69
0-62
0-54
0-51
0-49
0-55
0-42
0-55
0-52
O-53±OO8
•Cumulative dose before reduction for 'patients converted' and total cumulative dose for 'patients not converted'.
Abbreviations: AF — atrial fibrillation, VHD — valvular heart disease, IHD — ischemic heart disease, HHD — hypertensive heart disease, CI — cardiothoracic index,
CCM — congestive cardiomyopathy, OHCM — obstructive hypertrophic cardiomyopathy, MVP — mitral valve prolapse, LBBB — left bundle branch block,
RBBB—right bundle branch block, SVT — supraventricular tachycardia.
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Table 2
Patient
30
43
44
48
9
10
12
14
21
23
25
26
29
34
37
41
45
49
Other treatment prescribed to try to achieve cardioversion
Treatment tried before the study and results
disopyramide
quinidine
quinidine
disopyramide, verapamil
negative
negative
negative
negative
quinidine, verapamil, disopyramide negative
quinidine
quinidine
none
quinidine
verapamil
none
none
none
none
none
none
none
none
negative
negative
negative
negative
Treatment tried after failure of flecainide
results
> responded to flecainide
)
amiodarone
electrical cardioversion
electrical cardioversion
disopyramide
none
disopyramide
amiodarone
amiodarone
amiodarone
electrical cardioversion
amiodarone, quinidine
electrical cardioversion
amiodarone, procainamide, quinidine
electrical cardioversion
amiodarone, quinidine
electrical cardioversion
amiodarone, quinidine
sotalol + lignocaine
quinidine, amiodarone
beta-blocker
and
positive
positive
positive
positive
negative
positive
negative
negative
positive
negative
negative
negative
positive
negative
negative
negative
positive
negative
negative
that in the group of patients not converted only 3
patients (21%) did not exhibit organic heart dis-
ease. In the group of patients converted there were
18 patients without organic heart disease, i.e. 50%.
There was no difference between the two groups as
regards the age of patients
OTHER TREATMENT
No patient received any other anti-arrhythmic
drug for the duration of the study. Twelve patients
(85%) were digitalized in the group of those not
converted, and 22 patients (61%) received digitalis
in the group of converted patients. One female
patient was under treatment with a beta blocker
for obstructive cardiomyopathy. Moreover, she
did not respond to the treatment.
DOSE AND DOSAGE OF FLECAINIDE
The cumulative doses of flecainide before con-
version were 2-59±2-36mg kg"1 in the group of
patients converted, and 8-26+ l-96mg kg"1 in the
group of those not converted. The concentration
of flecainide at the time of conversion was
402 +427 ng ml"1. Seven hours after conversion
this concentration was 363-6± 195 ng ml" ' . In the
group of patients not converted 7 hours after the
last oral dose, the mean concentration was
386-8 ± 205 ng ml" ' (difference not significant).
SIDE-EFFECTS
Side-effects attributable with certainty to the
drug were observed in 9 patients (Table 1). One
patient exhibited hyperthermia with no apparent
cause on the day after treatment was initiated.
Although it was impossible to attribute this with
any certitude to flecainide, the treatment was
terminated.
The drug had to be discontinued in 5 patients
(10%): in 2 cases due to the occurrence of bundle
branch block, in 2 cases due to the occurrence of a
2nd-degree sino-atrial block type II, and in one
case of hyperthermia already referred to. In the 4
remaining patients, the side-effects disappeared
after 2 days of treatment. We agree that it is
advisable not to administer flecainide to patients
exhibiting conduction disorders. Apart from con-
duction disorders, the side-effects are not very
frequent and only necessitate termination of
treatment in exceptional cases.
Discussion
EFFICACY
Our results show that flecainide is an effective
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drug for the conversion of supraventricular
arrhythmias to sinus rhythm, in particular for
atrial fibrillation with a success rate of 75% and for
junctional tachycardias with a success rate of
100%. The rate of conversion achieved for atrial
fibrillation and SV tachycardia is higher than with
other anti-arrhythmic drugs" !" l 51 used singly. An
excellent association described by Stern'201 is that
combining beta blockers with quinidine. Treat-
ment with beta blockers is, however, not always
possible in patients who are in the majority of cases
elderly, and in addition, the side-effects of
quinidine are quite frequent and sometimes
inconvenient, and quite often necessitate termina-
tion of treatment."5-261.
In these studies, moreover, the duration of the
atrial fibrillation is not always reported, whilst in
our study it was short, and it has been shown that
the duration of the atrial fibrillation"81 is one of
the principal factors in achieving conversion to and
maintenance of sinus rhythm. Kayden et al. and
Fenster et al.ll6A1] have also recorded that for
fibrillation which has persisted for more than 15
days the conversion rate was notably lower than
for that which had lasted less than 15 days. Our
results are in agreement with this, although there
was no statistically significant difference. We con-
verted 79% of fibrillations which had appeared less
than 15 days before and only 64% of those which
had appeared more than 15 days before. In
addition, our group of patients undoubtedly
includes some in whom the rhythm disorder would
have been paroxysmal and which would have
reverted spontaneously. In particular, atrial fibril-
lation is paroxysmal in 9 to 35% of those free from
organic heart disease. Only 1/3 of these patients
will develop persistent atrial fibrillation"91. It is,
however, impossible to predict with certainty
which patient will develop transitory arrhythmia.
With regard to SV tachycardia, although the num-
ber of cases is small, the efficacy of flecainide is
noteworthy because all the patients were con-
verted. This is in agreement with Hellestrand et
a/.'91. In the case of atrial flutter, although the
number of cases is again small, efficacy does not
appear to be as good because the success rate is
only 33%, and the duration of the arrhythmia
does not appear to play any part. Studies involving
a larger number of patients are necessary to deter-
mine whether flecainide is ineffective in converting
atrial flutter or whether the low success rate is
attributable to the small number of cases. One
should also note that of the 14 patients who did not
respond to treatment, only 4 were converted by
other anti-arrhythmic drugs and in the converted
group that 4 patients had received a different anti-
arrhythmic agent without success, before being
converted with flecainide.
A crucial problem in our study was to estimate
the relative proportion of spontaneous conversion
and conversion by flecainide. In the 19 patients
who were converted within 3 h, conversion could
be attributed to flecainide. In the 17 remaining
patients it is impossible to tell whether conversion
was spontaneous or not. For the 10 patients in
whom arrhythmia was present for more than one
day it is highly probable that the drug was effi-
cacious. In the 7 other patients, the delay before
conversion is long compared to the duration of the
arrhythmia: we cannot therefore prove that the
conversion was not spontaneous, particularly in
patient number 24, who presented with SVT, an
arrhythmia which is usually quickly converted by
drugs.
AETIOLOGY
There was no type of heart disease represented
more frequently in the group of patients who
responded to treatment than in that which did not.
One significant difference is that patients without
organic heart disease are clearly more numerous in
the group converted. It is known that atrial fibril-
lation is more difficult to convert and recurs with
greater ease if organic heart disease is present'211.
We might comment that the patients converted
had a cardiothoracic index significantly lower than
the patients not converted. Sandee et a/.'221 earlier
described how patients with a heart volume of less
than 500 ml m~2 were more likely to be converted
than those with a volume greater than 700 ml m~2.
Although not all of the patients had an echo-
cardiogram, we nevertheless studied the size of the
left atrium, which was smaller in the group of
patients converted than in the group not con-
verted. This difference is not, however, statistically
significant. Fenster et a/.'161, Halpern et al. and
Henry et a/.'23>2*' have similarly shown that the
size of the left atrium is one of the important fac-
tors in determining the possibility of converting
atrial fibrillation to sinus rhythm and maintaining
it.
PLASMA CONCENTRATIONS
The mean serum concentrations which we
observed were within the normal range of those
usually recognized for ventricular arrhythmias,
namely from 200 to 1000 ng ml"1 '251 and the
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concentration in patients not converted were even
higher than those of patients converted. Thus it is
unlikely that the patients not converted received
insufficient flecainide. The doses we used therefore
seem to be quite adequate. The doses, calculated
cumulatively and averaged by bodyweight in kg,
were 2-59±2-36 mg kg" ' . The mean time required,
7-4 + 9 h, shows that the conversion is usually quite
rapidly achieved. No case was converted after 26 h,
and this makes us think that if the arrhythmia
persists after 1 day of treatment, it is pointless per-
sisting in attempting to convert it using flecainide.
Conclusion
We conclude that flecainide is a fast-acting drug
for the conversion to sinus rhythm of patients
exhibiting SV tachycardia or atrial fibrillation of
recent onset. Its efficacy is especially good if there
is no underlying heart disease, if the arrhythmia
has only been in existence a short time, if the car-
diothoracic index is normal and if the size of the
left atrium is normal. This treatment is particularly
useful in people who cannot undergo electrical
cardioversion or for whom quinidine is contra-
indicated. Its efficacy in cases of flutter has yet to
be evaluated.
We would like to thank Mrs S. Ward and the other staff at
Riker Laboratories in Loughborough, England, for their
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